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Abstract Antiangiogenic therapy has shown promise in
the treatment of patients with hepatocellular carcinoma
(HCC). Bevacizumab, sorafenib, and sunitinib showed
efficacy in patients with HCC; and sorafenib is approved
by the FDA for treatment of this cancer. In practice, the
clinical benefit of these agents has been heterogeneous; and
in patients who do respond, the benefit is modest and/or
short-lived. Recent advances in the molecular understand-
ing of tumor angiogenesis along with the rapid develop-
ment of targeted drug discovery have made it possible to
explore novel combination therapy for HCC. We review
the clinical trial results, discuss possible molecular
mechanisms of resistance, and suggest novel combinations
with antiangiogenic therapy.
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Introduction
Liver cancer is the fifth most common malignancy and the
third most common cause of cancer-related mortality
worldwide [1]. Even though more than 80% of the cases
occur in developing countries, its incidence continues to
increase in developed countries largely due to the Hepatitis
C epidemic [2]. Hepatocellular carcinoma (HCC) repre-
sents the major histologic subtype and accounts for an
estimated 70–85% of the cases [3]. Because of the
asymptomatic nature of early HCC, most patients present
with unresectable disease [4]. Presently, curative rates for
patients with advanced disease are dismal due to the
resistant nature of this malignancy to systemic chemo-
therapy. Unfortunately, local interventions such as
chemoembolization and ablation have failed to signifi-
cantly extend life expectancy [5]. And even in those who
undergo surgical resection, intrahepatic recurrence occurs
in 70% of the patients [6].
Recently, antiangiogenic therapy has shown promise in
the treatment of patients with HCC. This novel class of
agents was designed to inhibit the vascular endothelial
growth factor (VEGF) pathway; as VEGF is the most
prevalent and dominant proangiogenic growth factor in the
tumor microenvironment [7–10]. FDA approved agents
that directly target the VEGF pathway include the anti-
VEGF antibody bevacizumab and the multitargeted tyro-
sine kinase inhibitors (sunitinib, sorafenib, and pazopanib),
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which inhibit VEGFRs along with other receptor tyrosine
kinases [11–16].
At the present time, the factors/pathways that mediate
resistance to antiangiogenic therapy are unknown. In pre-
clinical models, there is evidence of compensatory path-
ways that mediate resistance at the levels of the tumor
blood vessels, microenvironment, and tumor epithelial
cells [17–21]. Antiangiogenic therapy may induce HIF-1a
and HIF-2a due to tumor blood vessel constriction,
decrease in blood flow, and induction of intratumoral
hypoxia [22, 23]. HIF-1a and HIF-2a, in turn, transactivate
gene programs important for inducing tumor angiogenesis,
cancer cell growth/survival, and energy metabolism;
mediating resistance. Like many other solid tumors, over-
expression of HIF-1a has been shown to occur in HCC and
its expression has been correlated with resistance to ther-
apy and confers a poor prognosis [24]. This overexpression
is triggered by tissue hypoxia, aberrant growth factor
receptor signaling, and mutations in oncogenes and tumor
suppressor genes.
Clinical trials with targeted agents in HCC (Table 1)
Sorafenib
Sorafenib is a small molecule, multi-targeted tyrosine
kinase inhibitor (TKI) that mediates its antiangiogenic
effect through inhibition of VEGFR-2/3 and PDGFR-b,
which direct the formation of new vasculature. Sorafenib
has been approved by the FDA for the treatment of hepa-
tocellular carcinoma and renal cell cancer.
The primary controlled studies indicating the potential
of single-agent sorafenib in the treatment of advanced HCC
are the SHARP (Sorafenib HCC assessment randomized
protocol) and Asian-Pacific trials. Sorafenib monotherapy
in the SHARP trial—a double-blind, placebo-controlled,
phase III study— proved efficacious in prolonging both
median overall survival (OS) and time to radiologic pro-
gression by 3 months. The sorafenib group recorded an OS
of 10.7 months as compared to 7.9 months for the placebo
control [15]. Patients in the sorafenib-arm showed a med-
ian time to radiographic progression of 5.5 months while
the placebo-arm was 2.8 months for the same parameter
[15]. Although sorafenib was therapeutically beneficial in
extending median OS and time to radiographic progression,
there was no significant difference in the time to symp-
tomatic progression between the sorafenib and placebo
groups. Only 2% of the patients in the sorafenib-arm
achieved a partial response (PR); without any complete
responses (CR) in either the sorafenib/placebo groups.
However, the disease control rate was substantially higher
in the sorafenib-arm versus the control-arm (43 to 32%)
[15].
Single-agent sorafenib in the Asian-Pacific trial patients
demonstrated a significant increase in median OS
(6.5 months) as compared to the median OS in the control
group (4.2 months). There was an increase in median time
to disease progression (TTP, 2.8 months) in the sorafenib
treatment group in comparison to the placebo group (TTP,
1.4 months) [25]. The clinical findings in the SHARP and
Asian-Pacific studies indicate the potential therapeutic
benefits of single-agent sorafenib in treating advanced
HCC.
In addition to its single-agent efficacy, sorafenib has also
shown a benefit when combined with doxorubicin. In a
phase I study of combined sorafenib/doxorubicin, all four
patients with metastatic HCC maintained stable disease
state for more than 1 year of treatment [26]. In a random-
ized, double-blind, phase II trial, sorafenib/doxorubicin
Table 1 Single-agent and combination therapy trials in HCC
Agent Phase ORR/PFSa/OSa Comments References
Sorafenib III NS/5.5/10.7 SHARP trial; time to radiologic progression Llovet et al [15]
III 3.3%/2.8/6.5 Asian-Pacific trial; time to progression Cheng et al. [25]
Sorafenib ? Doxorubicin I NS/–/– Noted that drug combination is well tolerated Richly et al [26]
II 8%/4.2/9.2 Keating et al. [27]
Bevacizumab II 13%/6.9/12.4 Serious bleeding occurred in about 11% of
patients
Siegel et al [32]
Bevacizumab ? Gemcitabine/Oxaliplatin II 20%/5.3/9.6 GEMOX-B Trial Zhu et al [33]
Bevacizumab ? Erlotinib II 25%/8.9/15.6 Thomas et al [34]
Sunitinib II NS/–/– European-Asian trial; trial did not proceed to
second phase due to low response rate
Faivre et al [35]
II 2.9/3.9/9.8 Zhu et al [36]
ORR objective response rate, PFS progression free survival, OS overall survival, NS no statistical significance between groups
a In months (values converted from those reported in the literature)
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combination failed to prolong median TTP; however, it
prolonged median OS and progression-free survival (PFS)
when compared to doxorubicin alone [27].
Sorafenib combined with transarterial chemoemboliza-
tion (TACE) is currently under clinical investigation [28,
29]. It is theorized that one of the reasons for the high local
recurrence rate after TACE is because of increased
expression of vascular growth factors and HIF-1a [30, 31].
A rational solution to this problem is to administer anti-
angiogenic agents concurrently or shortly after these
procedures.
Bevacizumab
Bevacizumab is a recombinant monoclonal anti-VEGF
antibody that has been approved by the FDA for the
treatment of advanced breast, non-squamous non-small cell
lung, and colorectal cancers when combined with chemo-
therapy. Bevacizumab is also approved for the treatment of
renal cell cancer in combination with IFN-a.
Siegal et al. [32] tested the efficacy of single-agent
bevacizumab in metastatic HCC in a phase II trial. Forty-
six patients were enrolled in this study; 12 patients received
5 mg/kg of bevacizumab and 34 patients received 10 mg/kg
of bevacizumab every two weeks until disease progression.
Of the 46 eligible patients, 13% had an objective response
and 65% were progression-free at 6 months. Overall sur-
vival at 1, 2, and 3 years was 58, 28, and 23%, respec-
tively; and median PFS was 6.9 months. In addition,
bevacizumab therapy resulted in substantially decreased
tumor enhancement upon dynamic contrast-enhanced MRI
and circulating VEGF concentrations. Therefore, single-
agent bevacizumab has shown promise in patients with
advanced HCC.
In the phase II GEMOX-B clinical trial, bevacizumab
was combined with an active chemotherapy regimen
(gemcitabine and oxaliplatin) in HCC [33]. In the first
cycle (14 days), 10 mg/kg of bevacizumab was adminis-
tered on day 1 followed by 10 mg/kg on days 1 and 15 in
subsequent cycles (28 days). Gemcitabine (1000 mg/m2)
and oxaliplatin (85 mg/m2) were administered on days 2
and 16. Thirty patients were assessed for efficacy in this
study; 20% of the patients demonstrated an objective
response, and 27% achieved stable disease (SD). Median
OS was 9.6 months and median PFS was 5.3 months.
In another phase II trial, bevacizumab was also tested in
combination with erlotinib [34]. Forty patients received
10 mg/kg of bevacizumab every 14 days and 150 mg of
oral erlotinib daily for 28 day cycles; anti-tumor activity
was analyzed every 2 cycles via RECIST criteria. Primary
end-point for this study was 16-week PFS with secondary
end-points of response rate (RR) and median PFS. The
16-week PFS was 62.5% and 10 patients had a partial
response (PR); median PFS was 39 weeks and the median
OS was 68 weeks. Overall, results from these phase II trials
suggest that bevacizumab in combination with other agents
may be additive, warranting randomized trials.
Sunitinib
Sunitinib is a multi-targeted TKI that inhibit VEGFR-1/2/3,
PDGFR-a/b, c-kit, FLT3, and RET kinases. Sunitinib has
received FDA approval for the treatment of renal cell
carcinoma and gastrointestinal stromal tumors. There have
been two phase II clinical trials focusing on the efficacy of
sunitinib monotherapy in advanced HCC.
The European/Asian trial included 37 patients receiving
50 mg daily sunitinib on a 4 weeks on and 2 weeks off
schedule (6 week/cycle; 4/2 schedule) [35]. The primary
end-point and determinant of efficacy in this trial was
overall RR via RECIST criteria with an expected RR of
15%. However, only one patient displayed PR; therefore,
outcome was well below the desired primary end-point of
15% with an actual RR of 2.7%. Thirteen patients had SD
over 3 months. In addition to less than expected response
rates, there was severe, adverse events leading to the death
of four patients from GI perforations, encephalopathy, and
hepatorenal syndrome.
In another phase II study by Zhu et al. [36], 34 patients
with unresectable HCC were treated with sunitinib 37.5 mg
daily for 28 days followed by 14 days of rest in 6-week
cycles (4/2 schedule). The primary end-point of this trial
was PFS. Even though the 3-month PFS rate failed to meet
the authors’ predefined targeted end point of 59%, results
were nonetheless encouraging showing an objective RR of
2.9%, median PFS of 3.9 months and median overall sur-
vival of 9.8 months. Adverse events were modest. Grade 3
and 4 toxicities occurred in less than 20% of the patients in
any particular category and most commonly included my-
elosuppression, fatigue and transaminase abnormalities.
Moreover, analysis of response of vessel integrity to single-
agent sunitinib demonstrated a drastic reduction in vascular
permeability; and measurement of angiogenic plasma
proteins and inflammatory cytokines showed that these
biomarkers are significantly altered by sunitinib.
Mechanism of resistance to antiangiogenic therapy
Although the inhibition of tumor blood vessel formation
has shown clinical efficacy, treatment resistance inevitably
develops through a variety of mechanism. First, resistance
can occur at the tumor endothelial cell level; evidence has
shown that tumor endothelial cells may harbor unstable
genomes [37]. These aberrant genomes may lead to an
increase in genetic alterations and the propagation of
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mutations in subsequent endothelial cell lines. These
altered cell lines may acquire resistance to molecularly
targeted antiangiogenic therapy.
Another form of resistance may evolve from the
redundancy of angiogenic signaling pathways; tumor
dependence on a particular proangiogenic factor can be
altered while being subjected to antiangiogenic agents [38].
For instance, treatment with anti-VEGF agents may result
in vascular rearrangement and recruitment of excessive
pericytes through the overexpression of PDGF-b. The
vascular remodeling that results from pericytic over-cov-
erage renders the neovasculature less responsive to VEGF
for growth dependance effectively circumventing a
blocked signaling pathway with a heavier dependence on
an alternate mechanism.
Thirdly, antiangiogenic therapy may lead to the sus-
ceptibility of a tumor for metastatic spread. It has been
shown that inhibition of both VEGFR and PDGFR results
in an increased propensity for metastatic dissemination
because the newly created hypoxic microenvironment
selects for highly aggressive, invasive tumor cells [21].
Blagosklonny [39] elegantly hypothesized that antiangio-
genic therapy may lead to increased intratumoral hypoxia
and select for highly aggressive, metastatic tumor cells.
Tumors can also evade antiangiogenic therapy by
acquiring the ability to grow without neovasculature. For
instance, tumor cells may grow via a process known as
‘‘vascular cooption,’’ which is characterized by neoplastic
cells growth around pre-existing, normal tissue vascula-
ture; these tumor cells acquire oxygen and nutrients from
normal tissue blood vessels [40]. Antiangiogenic mecha-
nisms inhibit sprouting angiogenesis which relies on the
need for endothelial cell proliferation and migration.
Tumor cells can evade these pruning effects via intussus-
ception; a process characterized by the splitting of pre-
existing vasculature into new blood vessels without a need
for VEGF expression and endothelial cell proliferation
[40].
A final obstacle for antiangiogenic therapy is vasculo-
genic mimicry, a process by which tumor cells form blood-
conducting vessels without the need for endothelial cell
proliferation [41].
Rationale for development of more effective
antiangiogenic therapy in HCC
Traditional strategies to design combination therapy in
clinical trials are to empirically combine agents with pro-
ven clinical efficacy. These strategies have been successful
in deriving effective combination treatment. With the
wealth of data available from molecular studies on tumor
angiogenesis, we can now rationalize novel combinations
which can be readily tested in preclinical models and then
clinical trials.
Treatment with the currently available antiangiogenic
agents including sunitinib, sorafenib, pazopanib, axitinib,
or bevacizumab would disrupt endothelial tubes and/or
pericytes through the inhibition of VEGF/VEGFR and
PDGF/PDGFR signaling pathways, respectively. Pericytes
are vascular smooth muscle cells that provide structural
support and stabilization for sprouting endothelial tubes
during vascular development. These support cells are
responsible for sustaining tumor angiogenesis via paracrine
production of VEGF. During tumor angiogenesis, cancer
cells and endothelial cells synthesize and secrete PDGF-b,
which acts in a paracrine fashion, stimulating pericytes to
express VEGF. Due to their function in the propagation of
tumor angiogenesis, pericytes serve as an important ther-
apeutic target in the treatment of highly vascular cancers.
Inhibiting both pericytes and endothelial cells would then
lead to more significant antiangiogenic effect than inhib-
iting endothelial cells alone. As such, selection of clinically
available agents with the most potent antiangiogenic effect
would involve disrupting both the VEGF/VEGFR and
PDGF/PDGFR pathways. This would include agents like
sorafenib, sunitinib, pazopanib, and axitinib.
Despite maximal inhibition of VEGF/VEGFR and
PDGF/PDGFR pathways, resistance reliably develops due
to a process known as ‘‘reactive resistance’’ [39]. Effective
antiangiogenic therapy works by creating a hypoxic con-
dition devoid of nutrients for sustained cellular growth/
survival. However, intratumoral hypoxia leads to the
induction of compensatory pathways that mediate resis-
tance at the levels of the tumor blood vessels, microenvi-
ronment, and tumor epithelial cells [17, 18]. In preclinical
models, the hypoxia-inducible factors, HIF-1a and HIF-2a,
have been shown to be major mediators of reactive resis-
tance [21, 42] (Fig. 1). HIF-1a and HIF-2a induction would
lead to the modulation of [200 genes important for
inducing tumor angiogenesis, cancer cell growth/survival,
and energy metabolism; mediating resistance [43, 44]. In
addition to mediating reactive resistance, HIF-1a and HIF-
2a also mediate primary resistance due to their induction
through dysregulated growth signaling by inflammatory
mediators, growth factors, and mutations in cancer genes
[45–54]. Like many other solid tumors, overexpression of
HIF-1a and HIF-2a has been shown to occur in HCC and
may mediate resistance to therapy [24].
Thus, combining agents that inhibit HIF-1a and HIF-2a
with effective antiangiogenic agents, such as sorafenib,
sunitinib, pazopanib, or axitinib would counteract reactive
resistance and other driving forces of carcinogenesis. In
combination with antiangiogenic agents, inhibiting both
HIF-1a and HIF-2a would further disrupt tumorigenesis
through two potential mechanisms. The first mechanism of
180 Oncol Rev (2011) 5:177–184
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synergy is by modulation of additional angiogenic path-
ways that complement those affected by the currently
available antiangiogenic agents [18]. We recently reported
that inhibition of HIF-1a and HIF-2a in cancer cells
improved the antiangiogenic effect of sunitinib due to the
inhibition of the proangiogenic factor, ANGPTL4, and
induction of the antiangiogenic factor, TSP1 [42]. The
second mechanism of synergy is through the direct effects
of inhibiting HIF-1a and HIF-2a on tumor epithelial cell
growth. HIF-1a and HIF-2a can be induced in cancer cells
through dysregulated growth signaling by inflammatory
mediators, growth factors, and mutations in cancer genes.
In addition to tumor angiogenesis, HIF-1a and HIF-2a are
responsible for a multitude of cellular processes that reg-
ulates growth/survival, invasion, and metastatic potential
of tumor cells [55]. Altogether, inhibiting both HIF-1a and
HIF-2a would effectively counteract the development of
resistance to antiangiogenic therapy; since the effects of
HIF inhibition would be seen in both endothelial cells and
tumor cells.
To date, high-throughput small-compound screens and
mechanistic studies have identified several classes of
anticancer agents that disrupt HIF-1a function, including
inhibition of its transcriptional activity and HIF-1a protein
synthesis or stability [56–59]. Based on partial structural
and functional similarities between HIF-1a and HIF-2a, it
is possible that many of the already identified HIF-1a
inhibitors would inhibit HIF-2a. In addition, systematic
efforts are currently ongoing to identify compounds that


























































Fig. 1 Diagram depicting the tumor microenvironment and mecha-
nism of known HIF inhibitors. HIF-a is overexpressed in cancer cells
and stromal cells, promoting tumor angiogenesis by inducing the
production of VEGF and other proangiogenic factors. HIF inhibitors
work by disrupting HIF-a protein synthesis, stability, or transcrip-
tional activity. PHD prolyl hydroxylase, HIF-a hypoxia-inducible
factor-a, HIF-b hypoxia-inducible factor-b, pVHL von Hippel-Lindau
protein, HDAC histone deacetylase, HSP90 heat shock protein 90,
mTOR mammalian target of rapamycin, p300 transcriptional coacti-
vator p300, EGFR epidermal growth factor receptor, VEGF vascular
endothelial growth factor, PDGF platelet-derived growth factor
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cancer treatment [44, 60]. Many of these HIF inhibitors are
currently in phase I and II clinical trials (Table 2 and
Fig. 1).
Antiangiogenic therapy has revolutionized the treatment
of HCC. Sorafenib has recently been approved for the
treatment of advanced HCC; with other antiangiogenic
agents, bevacizumab and sunitinib, showing promising
activity. Future clinical development in HCC should
include trials with HIF inhibitors, particularly in combi-
nation with antiangiogenic drugs. Appropriate doses and
sequencing of these agents would need to be tested in
preclinical models to help with clinical trial design.
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